Aeglea biotherapeutics, inc. (AGLE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-79,815

-78,254

-71,657

-62,001

-53,396

-44,348

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

0

-23,398

-

-20,202

-17,377

-13,374

-11,295

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

472

418

384

355

323

293

287

280

267

249

219

184

155

132

125

116

101

89

0

0

0

Purchase net discount on marketable securities

-280

-504

0

0

0

-

-

-

-

-9

0

0

0

-

-

-

-

-

-

-

-

Net accretion of discount on marketable securities

591

818

1,031

1,029

854

593

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net (accretion of discount) amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Purchase premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Amortization of lease allowance liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23

-

0

0

0

Stock-based compensation

5,143

4,876

5,069

4,775

4,526

4,280

3,601

3,257

2,926

2,492

2,052

1,758

1,482

1,221

1,382

1,112

869

767

0

0

0

Research and development services settled with stock

-

-

-

-

-

107

0

0

0

-

-

-

-

110

197

322

626

812

0

0

0

Non-cash operating lease expense

566

483

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other, net

-

-

-

-

-

40

36

28

27

21

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable - grant

-

-

-

-

-

-3,078

-30

3,068

2,392

1,863

881

-412

-637

-482

0

0

0

-

-

-

-

Prepaid expenses and other assets

2,114

346

441

1,911

1,087

261

1,909

716

367

114

-612

208

342

924

1,319

1,043

837

586

0

0

0

Accounts payable

556

2,583

1,346

1,801

2,132

239

444

403

465

164

92

160

-174

-8

-39

-441

110

-169

0

0

0

Deferred revenue

-

-

-

-

-

-20

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-236

-258

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Accrued and other liabilities

4,165

5,125

6,282

4,792

3,277

4,165

2,365

1,707

1,536

1,666

1,006

582

1,267

1,829

1,810

2,274

1,668

1,119

0

0

0

Net cash used in operating activities

-71,579

-65,692

-56,598

-47,892

-40,553

-32,193

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

0

-20,284

-

-15,318

-13,264

-12,487

-10,982

0

0

0

Purchases of property and equipment

2,763

1,492

521

479

457

422

410

420

431

619

549

438

481

212

131

265

200

208

0

0

0

Purchases of marketable securities

76,176

91,926

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

78,017

91,679

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

62,115

55,230

50,230

20,390

0

0

0

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

39,550

-

37,850

21,690

14,136

8,446

0

0

0

-

-

-

-

Net cash provided by investing activities

-922

-1,739

-14,197

-28,810

-5,997

-15,231

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of offering costs

-

64,298

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

0

-36,495

-

-15,145

-3,310

-5,186

-4,014

0

0

0

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,679

0

0

0

Proceeds from employee stock plan purchases and stock option exercises

1,340

1,450

1,693

2,409

2,731

3,020

2,837

1,798

1,425

833

0

0

0

-

-

-

-

-

-

-

-

Principal payments on finance lease obligation

26

25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

950

65,723

82,308

83,053

121,435

57,068

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

-71,551

-1,708

11,513

6,351

74,885

9,644

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

0

49,564

-

49,167

48,121

-2,102

41,674

0

0

0

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

0

-7,215

-

18,704

31,547

-19,775

26,678

0

0

0

Supplemental Disclosure of Non-Cash Investing and Financing Information:
Leased assets obtained in exchange for lease obligations

4,655

5,294

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid amounts related to purchase of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

0

0

Deemed dividend to Series A convertible preferred stockholders upon conversion from an LLC to corporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

228

0

0

0